Trials / Recruiting
RecruitingNCT06562647
SY001 Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors
An Exploratory Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of SY001 Injection Targets Mesothelin in a Single-arm, Dose-increasing Setting in Subjects With Advanced Solid Tumors
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 2 (estimated)
- Sponsor
- Cell Origin Biotech (Hangzhou) Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Single-arm, dose-increasing setting study of CAR macrophages in Mesothelin overexpressing solid tumors.
Detailed description
This study was a single-arm, single-center, dose-increasing design, using the "3+3" approach for dose escalation, to evaluate the safety, tolerability and initial effectiveness of SY001, and to evaluate the pharmacokinetic characteristics, cytokines and the correlation between the efficacy of SY001.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SY001 | PBMC-derived anti-mesothelin Cheimeric Antigen Receptor macrophages |
Timeline
- Start date
- 2023-04-12
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2024-08-20
- Last updated
- 2026-02-13
Locations
2 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06562647. Inclusion in this directory is not an endorsement.